Category: Impacting News

Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Hepion Pharmaceuticals’ Product CRV431 Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH“) and chronic viral infection, today announced that the peer-reviewed Journal of Pharmacology and Experimental Therapeutics has published Hepion’s research article entitled, “A Pan-Cyclophilin …
Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314

Results From Phase I/IIa Trial of RegenxBio Gene Therapy Product RGX-314

RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio (RGNX) announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Here are the results as presented by the Company. The results were presented by Jeffrey S. Heier, M.D., Co-President and Director of Retina Research at Ophthalmic Consultants of Boston and primary investigator for the trial, in a …
Moderna’s Investigational Zika Vaccine Is Granted FDA Fast Track Designation

Moderna’s Investigational Zika Vaccine Is Granted FDA Fast Track Designation

From Moderna  From the press release we learned that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Moderna’s (MRNA) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults. This is good news for Moderna as the Fast Track designation will facilitate the development of mRNA-1893 for Zika …
A Press Release About Regeneron’s Product REGN-EB3 Showing Superiority in Preventing Ebola Deaths

A Press Release About Regeneron’s Product REGN-EB3 Showing Superiority in Preventing Ebola Deaths

PALM EBOLA CLINICAL TRIAL STOPPED EARLY AS REGENERON’S REGN-EB3 THERAPY SHOWS SUPERIORITY TO ZMAPP IN PREVENTING EBOLA DEATHS TARRYTOWN, N.Y., Aug. 12, 2019,/PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study investigators that a randomized, controlled trial evaluating four investigational therapies for Ebola virus infection was stopped early because REGN-EB3 was superior to ZMapp in preventing death. ZMapp served …
Court Upholds Validity of Amgen’s Claims Regarding Enbrel

Court Upholds Validity of Amgen’s Claims Regarding Enbrel

Amgen Press release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed to Enbrel Preliminary Injunction to Remain in Place THOUSAND OAKS, Calif., Aug. 9, 2019, /PRNewswire/ — Amgen (AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen’s favor on the validity of the two patents that describe and claim Enbrel® (etanercept) and methods for making it. Amgen affiliates Immunex …
Nektar’s Q2 Press Release

Nektar’s Q2 Press Release

Nektar’s Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December 31, 2018.  “Nektar is making good progress advancing our multiple programs in immuno-oncology, immunology, and pain,” said Howard W. Robin, President, and CEO of Nektar. “With our partner Bristol-Myers Squibb, …
Impacting News

Impacting News

In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. Only a few of these press releases have any impact, whether it be positive or negative, on the firms’ that are the subject of these press releases. Prohost’s Impacting News column will contain only those press releases that have news with a tremendous impact on the firms’ that are …